$PFE · Pfizer Inc.
EPS
0–0
DIR
1–0
MAE
+0.2%
Latest call · 2026-05-04
The call
EPS
$0.78
BEAT· +8.3% vs street
Direction
🟢 UP
1d +1.0% · 3d +1.5%
Confidence
MEDIUM
Positioning: hype_washed_out
Spot at call
$26.29
as of 2026-05-04
Head-to-head · Claude vs the Street vs reality
| Claude | Street | Actual | |
|---|---|---|---|
| EPS | $0.78 | $0.72 | — |
| Revenue | $13.95B | $13.82B | — |
| Direction (1d) | 🟢 UP |
🟡 FLAT
8B · 14H · 4S
|
🟢 UP |
| 1d move | +1.0% | — | +0.8% |
| 3d move | +1.5% | — | — |
EPS
—
Direction
Claude
Thesis
Defensive 6.6%-yielder with rock-bottom expectations (95% Polymarket beat odds). Cost-program leverage under Bourla's $4.5B savings target should drive an EPS beat to ~$0.78 vs $0.72 consensus. Edge is the Metsera GLP-1 broader cardiometabolic basket being mis-modeled as a single-asset replacement for failed danuglipron.
What would flip it
Eliquis Medicare price-negotiation commentary on the call flips a measured pop to flat.
💡 Defensive-yield beat-and-reaffirm. Long into print, trim into any +1.5% strength.
The market's narrative
Defensive 6.6%-yielder with structural LOE cliff (Eliquis, Vyndaqel, Ibrance, Xeljanz, Xtandi) and a freshly reset GLP-1 strategy after danuglipron's 2025 discontinuation — Polymarket 95% beat odds say the bar is rock-bottom.
Where the Street may be wrong
- Cost-program execution under Albert Bourla's $4.5B opex savings target running ahead of schedule — Q1 should show outsized SG&A leverage that maps to a ~$0.78 EPS print vs $0.72 consensus.
- Metsera MET-097i ultra-long-acting GLP-1 (once-monthly subcu) is being valued by the Street as a single-asset replacement for danuglipron, but the broader cardiometabolic basket adds an under-modeled call option.
Peer read: VZ +1.55% on 4/24 (defensive-yield + skeptical-positioning beat-and-raise template) — same setup type
Reasoning
- $2.80-3.00 FY26 EPS guide given in Feb is unchanged base — Q1 print only needs to track within the range to release the defensive-yield rotation amplifier.
- 6.6% dividend yield + COVID franchise comps now anniversaried = floor on the multiple regardless of LOE narrative.
- RSI 41 + price sitting on 50EMA $26.12 = no positioning pressure, low-implied-vol setup.
- 8 Buy / 14 Hold / 4 Sell rating mix = mostly Hold, no upgrade-cycle latent — but no downgrade fuel either.
- Cost program leverage drives the EPS beat; revenue likely modestly above $13.82B as Vyndaqel + ABRYSVO offset COVID decline.
Risks to the call
- Eliquis Medicare price-negotiation commentary on the call resets near-term Eliquis growth assumption — could flip a +1% reaction to flat.
- Any GLP-1 / Metsera pipeline timeline slip would re-open the bear thesis.